Advancing Abuse Deterrence: Is Delaying Opioid Extraction Enough?
Executive Summary
As the technology improves, so should the minimum expectations to gain an abuse-deterrent labeling claim, FDA advisory committee members say during review of Pfizer's oxycodone/naltrexone extended-release combination Troxyca.